Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (NCT03298451)
A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
🩺 Plain-English Summary (8th-Grade Level)
This is a randomized, open-label, multi-center, global, Phase III study to assess the efficacy and safety of durvalumab plus tremelimumab combination therapy and durvalumab monotherapy versus sorafenib in the treatment of patients with no prior systemic therapy for unresectable HCC. The patients cannot be eligible for locoregional therapy
Who can join: Review the eligibility criteria below.
Location: Research Site — Los Angeles, California
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (160 Sites)
Showing the first 25 of 160 sites.
- Research Site — Los Angeles, California
- Research Site — Orange, California
- Research Site — San Francisco, California
- Research Site — Washington D.C., District of Columbia
- Research Site — Fort Myers, Florida
- Research Site — Jacksonville, Florida
- Research Site — Westwood, Kansas
- Research Site — Baltimore, Maryland
- Research Site — Ann Arbor, Michigan
- Research Site — Rochester, Minnesota
- Research Site — New York, New York
- Research Site — Charlotte, North Carolina
- Research Site — Portland, Oregon
- Research Site — Pittsburgh, Pennsylvania
- Research Site — Dallas, Texas
- Research Site — Dallas, Texas
- Research Site — Dallas, Texas
- Research Site — Houston, Texas
- Research Site — Houston, Texas
- Research Site — Murray, Utah
- Research Site — Barretos,
- Research Site — Curitiba,
- Research Site — Florianópolis,
- Research Site — Porto Alegre,
- Research Site — Rio de Janeiro,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Hepatocellular Carcinoma
- TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients — Maywood, Illinois
- Cryoablation and Arterial Infusion of SD-101 in Combination With Durvalumab and Tremelimumab — San Diego, California
- Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC) — Baltimore, Maryland
- TheraSphere With Durvalumab and Tremelimumab for HCC — San Diego, California
- Blood Salvage in Orthotopic Liver Transplantation With HCC — Toronto, Ontario
- Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) — Prescott Valley, Arizona
Explore by condition: All Hepatocellular Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.